.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,150,530

« Back to Dashboard

Details for Patent: 6,150,530

Title: Retroviral protease inhibiting compounds
Abstract:A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.
Inventor(s): Kempf; Dale J. (Libertyville, IL), Norbeck; Daniel W. (Crystal Lake, IL), Sham; Hing Leung (Gurnee, IL), Zhao; Chen (Gurnee, IL), Sowin; Thomas J. (Grayslake, IL), Reno; Daniel S. (Kenosha, WI), Haight; Anthony R. (Park City, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Filing Date:Dec 08, 1998
Application Number:09/207,881
Claims:1. A process for the preparation of a compound of the formula: ##STR18## wherein R.sub.1 is monosubstituted thiazolyl, monosubstituted oxazolyl, monosubstituted isoxazolyl or monosubstituted isothiazolyl wherein the substituent is selected from (i) C.sub.1 - to -C.sub.6 -loweralkyl, (ii) C.sub.1 -to -C.sub.6 -loweralkenyl, (iii) C.sub.3 - to -C.sub.7 -cycloalkyl, (iv) C.sub.3 - to -C.sub.7 -cycloalkyl -C.sub.1 - to -C.sub.6 -alkyl, (v) C.sub.5 - to -C.sub.7 -cycloalkenyl, (vi) C.sub.5 - to -C.sub.7 -cycloalkenyl -C.sub.1 - to -C.sub.6 -alkyl, (vii) C.sub.1 - to -C.sub.6 -alkoxy -C.sub.1 - to -C.sub.6 -alkyl or benzyloxy -C.sub.1 - to -C.sub.6 -alkyl, (viii) C.sub.1 - to -C.sub.6 -thioalkoxy -C.sub.1 - to -C.sub.6 -alkyl or benzyl-S-C.sub.1 - to -C.sub.6 -alkyl, (ix) C.sub.1 - to -C.sub.6 -alkylamino, (x) di-C.sub.1 - to -C.sub.6 -alkylamino, (xi) phenyl wherein the phenyl ring is unsubstituted or substituted with a substituent selected from halo, C.sub.1 - to -C.sub.6 -loweralkyl, hydroxy, C.sub.1 - to -C.sub.6 -alkoxy, benzyloxy, -S-benzyl and C.sub.1 - to -C.sub.6 -thioalkoxy, (xii) phenyl -C.sub.1 - to -C.sub.6 -alkyl wherein the phenyl ring is unsubstituted or substituted as defined above, (xiii) di -C.sub.1 - to -C.sub.6 -alkylamino -C.sub.1 - to -C.sub.6 -alkyl, (xiv) C.sub.1 - to -C.sub.6 -alkoxy or benzyloxy and (xv) C.sub.1 - to -C.sub.6 -thioalkoxy or -S-benzyl;

n is 1, 2 or 3;

R.sub.2 is hydrogen or C.sub.1 - to -C.sub.6 -loweralkyl;

R.sub.3 is C.sub.1 - to -C.sub.6 -loweralkyl;

R.sub.4 and R.sub.4a are independently selected from phenyl, thiazolyl and oxazolyl wherein the phenyl, thiazolyl or oxazolyl ring is unsubstituted or substituted with a substituent selected from (i) halo, (ii) C.sub.1 - to -C.sub.6 -loweralkyl, (iii) hydroxy, (iv) C.sub.1 - to -C.sub.6 -alkoxy or benzyloxy and (v) C.sub.1 - to -C.sub.6 -thioalkoxy or -S-benzyl;

R.sub.6 is hydrogen or C.sub.1 - to -C.sub.6 -loweralkyl;

R.sub.7 is thiazolyl, oxazolyl, isoxazolyl or isothiazolyl wherein the thiazolyl, oxazolyl, isoxazolyl or isothiazolyl ring is unsubstituted or substituted with C.sub.1 - to -C.sub.6 -loweralkyl; and

Z is absent, --O--, --S--, --CH.sub.2 -- or --N(R.sub.8)-- wherein R.sub.8 is C.sub.1 - to -C.sub.6 -loweralkyl, C.sub.3 - to -C.sub.7 -cycloalkyl, --OH or --NHR.sub.8a wherein R.sub.8a is hydrogen or C.sub.1 - to -C.sub.6 -loweralkyl; or a pharmaceutically acceptable salt thereof, comprising reaction of a compound of the formula: ##STR19## or a salt thereof wherein R.sub.4, R.sub.4a, R.sub.6 and R.sub.7 are as defined above with an activated ester derivative of a compound of the formula: ##STR20## wherein R.sub.1, R.sub.2, R.sub.3, Z and n are as defined above.

2. The process of claim 1 wherein R.sub.1 is C.sub.1 - to -C.sub.6 -loweralkyl-substituted thiazolyl, R.sub.2 is hydrogen, R.sub.3 is C.sub.1 - to -C.sub.6 -loweralkyl, R.sub.4a and R.sub.4 are phenyl, R.sub.6 is hydrogen, R.sub.7 is thiazolyl and n is 1.

3. The process of claim 2 wherein Z is --N(CH.sub.3)--.

4. The process of claim 1 wherein R.sub.1 is isopropyl-substituted thiazolyl, R.sub.2 is hydrogen, R.sub.3 is isopropyl, R.sub.4a and R.sub.4 are phenyl, R.sub.6 is hydrogen, R.sub.7 is thiazolyl, n is 1 and Z is --N(CH.sub.3)--.

5. The process of claim 1 wherein the activated ester derivative is an ester derived from N-hydroxysuccinimide, an ester derived from N-hydroxyphthalimide, an ester derived from N-hydroxybenzotriazole, an ester derived from N-hydroxy-5-norbornene-2,3-dicarboxamide or an ester derived from 2,4,5-trichlorophenol.

6. A process for the preparation of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)car bonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl -3-hydroxyhexane or a pharmaceutically acceptable salt thereof, comprising reacting (2S,3S,5S)-5-(amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-dipheny l-3-hydroxyhexane or a salt thereof with an activated ester derivative of N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valine.

7. The process of claim 6 wherein the activated ester derivative is an ester derived from N-hydroxysuccinimide, an ester derived from N-hydroxyphthalimide, an ester derived from N-hydroxybenzotriazole, an ester derived from N-hydroxy-5-norbornene-2,3-dicarboxamide or an ester derived from 2,4,5-trichlorophenol.

8. The process of claim 6 wherein the activated ester derivative is an ester derived from N-hydroxysuccinimide.

9. The process of claim 6 wherein the activated ester derivative is an ester derived from N-hydroxyphthalimide.

10. The process of claim 6 wherein the activated ester derivative is an ester derived from N-hydroxybenzotriazole.

11. The process of claim 6 wherein the activated ester derivative is an ester derived from N-hydroxy-5-norbornene-2,3-dicarboxamide.

12. The process of claim 6 wherein the activated ester derivative is an ester derived from 2,4,5-trichlorophenol.

13. An activated ester derivative of a compound of the formula: ##STR21## or a salt thereof wherein R.sub.1 is monosubstituted thiazolyl, monosubstituted oxazolyl, monosubstituted isoxazolyl or monosubstituted isothiazolyl wherein the substituent is selected from (i) C.sub.1 - to -C.sub.6 -loweralkyl, (ii) C.sub.1 - to -C.sub.6 -loweralkenyl, (iii) C.sub.3 - to -C.sub.7 -cycloalkyl, (iv) C.sub.3 - to -C.sub.7 -cycloalkyl -C.sub.1 - to -C.sub.6 -alkyl, (v) C.sub.5 - to -C.sub.7 -cycloalkenyl, (vi) C.sub.5 - to -C.sub.7 -cycloalkenyl -C.sub.1 - to -C.sub.6 -alkyl, (vii) C.sub.1 - to -C.sub.6 -alkoxy -C.sub.1 - to -C.sub.6 -alkyl or benzyloxy -C.sub.1 - to -C.sub.6 -alkyl, (viii) C.sub.1 - to -C.sub.6 -thioalkoxy -C.sub.1 - to -C.sub.6 -alkyl or benzyl-S-C.sub.1 - to -C.sub.6 -alkyl, (ix) C.sub.1 - to -C.sub.6 -alkylamino, (x) di -C.sub.1 - to -C.sub.6 -alkylamino, (xi) phenyl wherein the phenyl ring is unsubstituted or substituted with a substituent selected from halo, C.sub.1 - to -C.sub.6 -loweralkyl, hydroxy, C.sub.1 - to -C.sub.6 -alkoxy, benzyloxy, -S-benzyl and C.sub.1 - to -C.sub.6 -thioalkoxy, (xii) phenyl -C.sub.1 - to -C.sub.6 -alkyl wherein the phenyl ring is unsubstituted or substituted as defined above, (xiii) di-C.sub.1 - to -C.sub.6 -alkylamino -C.sub.1 - to -C.sub.6 -alkyl, (xiv) C.sub.1 - to -C.sub.6 -alkoxy or benzyloxy and (xv) C.sub.1 - to -C.sub.6 -thioalkoxy or -S-benzyl;

n is 1, 2 or 3;

R.sub.2 is hydrogen or C.sub.1 - to -C.sub.6 -loweralkyl;

R.sub.3 is C.sub.1 - to -C.sub.6 -loweralkyl; and

Z is absent, --O--, --S--, --CH.sub.2 -- or --N(R.sub.8)-- wherein R.sub.8 is C.sub.1 - to -C.sub.6 -loweralkyl, C.sub.3 - to -C.sub.7 -cycloalkyl, --OH or --NHR.sub.8a wherein R.sub.8a is hydrogen or C.sub.1 - to -C.sub.6 -loweralkyl; or a salt thereof.

14. The compound of claim 13 wherein R.sub.1 is C.sub.1 - to -C.sub.6 -loweralkyl-substituted thiazolyl, R.sub.2 is hydrogen, R.sub.3 is C.sub.1 - to -C.sub.6 -loweralkyl and n is 1.

15. The compound of claim 14 wherein Z is --N(CH.sub.3)--.

16. The compound of claim 13 wherein R.sub.1 is isopropyl-substituted thiazolyl, R.sub.2 is hydrogen, R.sub.3 is isopropyl, n is 1 and Z is --N(CH.sub.3)--.

17. The compound of claim 13 wherein the activated ester derivative is an ester derived from N-hydroxysuccinimide, an ester derived from N-hydroxyphthalimide, an ester derived from N-hydroxybenzotriazole, an ester derived from N-hydroxy-5-norbornene-2,3-dicarboxamide or an ester derived from 2,4,5-trichlorophenol.

18. An activated ester derivative of N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valine; or a salt thereof.

19. The compound of claim 18 wherein the activated ester derivative is an ester derived from N-hydroxysuccinimide, an ester derived from N-hydroxyphthalimide, an ester derived from N-hydroxybenzotriazole, an ester derived from N-hydroxy-5-norbornene-2,3-dicarboxamide or an ester derived from 2,4,5-trichlorophenol.

20. The compound of claim 18 wherein the activated ester derivative is an ester derived from N-hydroxysuccinimide.

21. The compound of claim 18 wherein the activated ester derivative is an ester derived from N-hydroxyphthalimide.

22. The compound of claim 18 wherein the activated ester derivative is an ester derived from N-hydroxybenzotriazole.

23. The compound of claim 18 wherein the activated ester derivative is an ester derived from N-hydroxy-5-norbornene-2,3-dicarboxamide.

24. The compound of claim 18 wherein the activated ester derivative is an ester derived from 2,4,5-trichlorophenol.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc